

Lisa Giulino-Roth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5286890/publications.pdf>

Version: 2024-02-01

34
papers

1,685
citations

516710

16
h-index

454955

30
g-index

35
all docs

35
docs citations

35
times ranked

3067
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1932-1946.	2.9	344
2	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. <i>Blood</i> , 2015, 125, 1061-1072.	1.4	281
3	Enhancer of zeste homolog 2 (EZH2) inhibitors. <i>Leukemia and Lymphoma</i> , 2018, 59, 1574-1585.	1.3	143
4	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	7.0	110
5	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted <sc>EPOCH</sc>. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	2.5	101
6	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. <i>Blood</i> , 2012, 120, 5181-5184.	1.4	96
7	Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. <i>Frontiers in Immunology</i> , 2018, 9, 2012.	4.8	79
8	Therapeutic options for CTLA-4 insufficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 736-746.	2.9	68
9	MYC Controls the Epstein-Barr Virus Lytic Switch. <i>Molecular Cell</i> , 2020, 78, 653-669.e8.	9.7	67
10	How I treat primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018, 132, 782-790.	1.4	61
11	Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1779-1790.	4.1	55
12	Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2013, 60, 2018-2024.	1.5	38
13	DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. <i>Nature Microbiology</i> , 2020, 5, 1051-1063.	13.3	32
14	Rituximab pharmacokinetics in children and adolescents with <i>de novo</i> intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. <i>British Journal of Haematology</i> , 2013, 162, 678-683.	2.5	31
15	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. <i>Blood Advances</i> , 2020, 4, 5226-5231.	5.2	28
16	Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents. <i>British Journal of Haematology</i> , 2015, 169, 647-660.	2.5	19
17	Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents. <i>Blood Advances</i> , 2019, 3, 4291-4297.	5.2	17
18	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, <i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. <i>OncImmunology</i> , 2019, 8, e1512455.	4.6	17

#	ARTICLE	IF	CITATIONS
19	Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. <i>Blood</i> , 2021, 137, 1449-1456.	1.4	16
20	Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children. <i>British Journal of Haematology</i> , 2016, 173, 531-544.	2.5	15
21	A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2 (EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4203-4203.	1.4	15
22	Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 1861-1870.	1.3	12
23	A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin's lymphomas (NHL), multiple myeloma (MM) and solid tumor.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2595-TPS2595.	1.6	11
24	A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. <i>Blood Advances</i> , 2022, 6, 3189-3193.	5.2	7
25	A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. <i>HemaSphere</i> , 2021, 5, e656.	2.7	6
26	Management of primary central nervous system lymphoma in children. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 386-389.	2.5	5
27	EZH2: a potential new target in T-cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1924-1925.	1.3	4
28	KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7583-TPS7583.	1.6	4
29	AYA Considerations for Aggressive Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 61-71.	2.3	1
30	Reducing radiation exposure in children with febrile neutropenia: can pulmonary MRI replace CT?. <i>Leukemia and Lymphoma</i> , 2016, 57, 4-5.	1.3	0
31	Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children's Oncology Group Study AHOD0031. <i>Blood</i> , 2016, 128, 924-924.	1.4	0
32	Primary Mediastinal and Gray Zone Lymphomas. , 2019, , 185-193.		0
33	Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7567-TPS7567.	1.6	0
34	The ABVD's of cooperative trials in pediatric Hodgkin lymphoma: The India experience. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	1.3	0